Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique
Large pharmaceutical companies dominate the dry eye disease space – Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops. Eight-person Oyster Point Pharma wants in on that market. But it’s betting on a completely different approach. “What we’ve come up with is a very innovative nasal spray, which when sprayed into the nose penetrates the naval cavity quite rapidly, binds to the [nicotinic acetylcholine] receptors, and can actually stimulate the patient’s natural tear production,” CEO Jeffrey Nau told Drug Delivery Business News. “It’s really the first of its kind in the pharmaceutical field to use this class of drugs to stimulate those receptors on the trigeminal nerve.” Get the full story at our sister site, Drug Delivery Business News. The post Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique appeared first on MassDevice.
Publication date: Available online 26 March 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Marcus S. Shaker, John Oppenheimer, Mitchell Grayson, David Stukus, Nicholas Hartog, Elena W.Y. Hsieh, Nicholas Rider, Cullen M. Dutmer, Timothy K. Vander Leek, Harold Kim, Edmond S. Chan, Doug Mack, Anne K. Ellis, David Lang, Jay Lieberman, David Fleischer, David B.K. Golden, Dana Wallace, Jay Portnoy, Giselle Mosnaim
BackgroundTemporary disruption of sensory input can be studied relatively easily for vision or hearing by covering the eyes or ears. In contrast, closing the nostrils affects not only the sense of smell, but also the ability to breathe through the nose and humidify and warm inhaled air. We hypothesized that filling the olfactory cleft (OC) with dissolvable nasal dressing (foam) would temporarily block olfaction while respecting nasal airflow.MethodsIn 30 healthy volunteers, the OC was unilaterally obstructed in a back ‐to‐front fashion. Orthonasal and retronasal olfactory function were tested before and after foam appl...
ConclusionsSkin exposure to peanut did not lead to sensitization in this study, and monkeys did not experience anaphylaxis upon peanut challenge. However, monkeys produced increased peanut ‐specific IgG throughout peanut exposure, indicating that repeated skin exposure to peanut is immunogenic.
The oral immunomodulator is indicated for treatment of adults with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.Medscape Medical News
This article is protected by copyright. All rights reserved.
One chart explains why slowing the spread of the infection is nearly as important as stopping it.
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News NIDCR News CDC’s COVID-19 Guidance for Dental Settings Dental health care personnel can find COVID-19-related information on the CDC’s Division of Oral Health website, which offers guidance and resources for clinics and health care facilities and recommen...
Conclusion: In patients with early-stage nasal NKTCL, our LVD-IMRT regimen produced excellent, durable therapeutic benefit in most patients, with acceptable toxicity and no acute mortality.